XTX Topco Ltd Takes Position in Hologic, Inc. (NASDAQ:HOLX)

XTX Topco Ltd purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 7,819 shares of the medical equipment provider's stock, valued at approximately $637,000.

Other large investors have also recently bought and sold shares of the company. State Street Corp grew its stake in Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider's stock valued at $847,944,000 after purchasing an additional 81,057 shares in the last quarter. FMR LLC grew its stake in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock valued at $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Hologic by 0.7% in the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider's stock valued at $208,051,000 after purchasing an additional 18,774 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Hologic by 8.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider's stock valued at $200,952,000 after purchasing an additional 195,285 shares in the last quarter. Finally, Black Creek Investment Management Inc. grew its stake in Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Trading Down 1.9 %

Shares of NASDAQ HOLX traded down $1.44 during midday trading on Friday, hitting $73.65. The stock had a trading volume of 2,553,387 shares, compared to its average volume of 1,626,827. The company's 50-day simple moving average is $79.45 and its 200 day simple moving average is $78.56. The firm has a market cap of $16.71 billion, a P/E ratio of 22.55, a price-to-earnings-growth ratio of 2.38 and a beta of 0.96. Hologic, Inc. has a fifty-two week low of $70.24 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. During the same period in the previous year, the firm earned $0.89 earnings per share. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Raymond James boosted their target price on Hologic from $93.00 to $95.00 and gave the company an "outperform" rating in a research note on Tuesday, November 5th. Jefferies Financial Group initiated coverage on Hologic in a research note on Tuesday. They set a "hold" rating and a $85.00 price target for the company. Evercore ISI upped their price target on Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a research note on Tuesday, October 1st. Needham & Company LLC reiterated a "buy" rating and set a $90.00 price target on shares of Hologic in a research note on Tuesday. Finally, Leerink Partners decreased their price target on Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $89.50.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.75% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.